Lipella Pharmaceuticals (LIPO) announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office, or USPTO, on November 12. This patent, titled “Delivery of Agents Using Metastable Liposomes,” covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles. The patent’s claims cover Lipella’s method of using metastable liposomes to deliver therapeutic agents, providing broad intellectual property protection for the company’s drug delivery platform. This protection extends market exclusivity for Lipella’s two lead clinical assets, LP-10 and LP-310, which are currently in Phase 2 clinical trials. LP-10, a liposomal formulation of tacrolimus for treating hemorrhagic cystitis, and LP-310, an oral rinse for managing oral lichen planus, represent promising new approaches to addressing diseases with limited treatment options.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals Inc trading halted, news pending
- Lipella Pharmaceuticals announces 1-for-8 reverse stock split
- Biotech Alert: Searches spiking for these stocks today
- Lipella announces U.S. patent allowance for liposomal drug delivery platform
- Lipella Pharmaceuticals reports early tolerability results in Phase 2a trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue